Skip to main content

Table 4 Renal function over 12 months (intent-to-treat population)

From: Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results

Visit window Everolimus 1.5 mg (n= 61)   MMF 2 g (n= 61)
n Mean (SD) Median (range) P value avs. MMF n Mean (SD) Median (range)
eGFR (MDRD) (ml/minute/1.73 m 2 )
Baseline 61 12.17 (6.23) 10.70 (4.7 to 41.1) 0.420 61 14.00 (8.37) 11.00 (2.7 to 41.1)
Month 1 56 63.10 (25.441) 58.40 (18.5 to 123.3) 0.685 60 60.53 (19.339) 57.25 (23.5 to 14.7)
Month 12 56 62.09 (18.993) 58.00 (17.8 to 123.3) 0.063 58 56.34 (15.227) 55.25 (26.1 to 111.8)
  <30 ≥30 to <60 ≥60 P value vs. MMF <30 ≥30 to <60 ≥60
Incidence rates of patients within renal function (eGFR MDRD) categories ( n /month, %)  
Month 1 5/56 (8.9) 26/56 (46.4) 25/56 (44.6) 0.541 1/60 (1.7) 31/60 (51.7) 28/60 (46.7)
Month 12 1/56 (1.8) 29/56 (51.8) 26/56 (46.4) 0.152 1/58 (1.7) 38/58 (65.5) 19/58 (32.8)
  1. aWilcoxon rank-sum test comparing everolimus and MMF values. eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; MMF, mycophenolate mofetil; SD, standard deviation.